
Faro Health is bringing clinical trials into the digital age by helping teams manage and balance the complexity of modern trial designs through a cloud native platform. The Faro platform enables study teams to design complex clinical trials using small modular building blocks and combines that with data driven insights to orchestrate and automate operationally complex trials. Faro brings balance, centricity and flexibility to protocol development through automation and integration to downstream systems and vendors, ensuring they are always up to date and correctly configured. As a result, clinical trials using Faro are operationally efficient which avoid delays due to ambiguity and generate data that can be trusted.

Faro Health is bringing clinical trials into the digital age by helping teams manage and balance the complexity of modern trial designs through a cloud native platform. The Faro platform enables study teams to design complex clinical trials using small modular building blocks and combines that with data driven insights to orchestrate and automate operationally complex trials. Faro brings balance, centricity and flexibility to protocol development through automation and integration to downstream systems and vendors, ensuring they are always up to date and correctly configured. As a result, clinical trials using Faro are operationally efficient which avoid delays due to ambiguity and generate data that can be trusted.
What they do: Cloud-native platform to design and automate complex clinical trial protocols
Founded / stage: Founded 2019 (reported); private, Series A / growth-stage
Team size: Reported 11–50 employees (profiles vary)
Known funding: $18.3M total reported (includes $15M Series A)
Leadership: Co-founder & CEO: Scott Chetham; Co-founder & CTO: Patrick Leung
Clinical trial design and operations; healthcare software for protocol authoring and workflow automation.
2019
Health care software
$15,000,000
Participation from Northpond Ventures, Polaris Partners and Zetta Ventures
$18,300,000
Company announcement referenced combined seed and Series A total of $18.3M
“Has institutional backers including Section 32, Northpond Ventures, Polaris Partners, Zetta Ventures, General Catalyst (listed as lead on a Series A entry in some profiles)”
| Company |
|---|